IP Library Granted Patent US 10,479,988
Granted Patent B2
US 10,479,988 · App. 15/720,336 · Granted Nov 19, 2019

Method of making a vaccine

Inventor: Kurt A. Garrett (Raleigh, NC)
Assignee: LUMAGENICS, LLC
C12N13/00A61K39/00C12N1/36A61K2039/522A61K2039/5254C12N7/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,479,988
App. No.
15/720,336
Granted
Nov 19, 2019
Kind
B2
Abstract

A method of producing attenuated cells for a mammalian vaccine comprising killing or attenuating the cells with a high energy, low heat UV light.

Claims (15)

1. A method of producing a live or dead attenuated infectious cells comprising:

a) isolating a plurality of infectious cells;

b) selecting a high energy UV light source that delivers a low heat UV containing light to the end of a light guide;

c) selecting the UV light source and output so that UV energy from the light source can selectively attenuate cells; and

d) exposing the infectious cells to the light from the end of the light guide at sufficient distance and wherein the cells are exposed to the light from about 0.1 seconds to about 5 seconds to attenuate the cells without damaging cellular proteins and carbohydrates that produce the immune response to produce attenuated cells.

2. The method according to claim 1 wherein the attenuated cells are formulated into a vaccine.

3. The method according to claim 2 wherein the vaccine is administered to a mammal in a dose effective to elicit an immune response that creates antibodies to the infectious cells.

4. A method of producing a live or dead attenuated infectious cells comprising:

a) isolating a plurality of infectious cells;

b) selecting a high energy UV light source having an output of at least about 80 lumens per watt that delivers a low heat UV containing light to the end of a light guide;

c) selecting the UV light source and output so that UV energy from the light source can selectively attenuate cells; and

d) exposing the infectious cells to the light from the end of the light guide at sufficient distance and time to attenuate the cells without damaging cellular proteins and carbohydrates that produce the immune response to produce attenuated cells.

5. The method according to claim 4 wherein the attenuated cells are formulated into a vaccine.

6. The method according to claim 5 wherein the vaccine is administered to a mammal in a dose effective to elicit an immune response that creates antibodies to the infectious cells.

7. The method according to claim 1 wherein the cells are exposed to the light from about 0.1 seconds to about 5 seconds.

Assignments (2)
CHANGE OF NAME Recorded Oct 14, 2019
From: HYPER LIGHT TECHNOLOGIES, LLC
To: LUMAGENICS, LLC
Reel/Frame 050704/0765 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2017
From: GARRETT, KURT A.
To: HYPER LIGHT TECHNOLOGIES, LLC
Reel/Frame 043741/0091 →
Continuity (1)
Related Publication 20190100743A1 · Apr 4, 2019